Gates Foundation Grant to address market need for high volume, affordable and rapid cycle time pharmaceutical proteins.
WILMINGTON, Del. (PRWEB) December 15, 2016
DuPont Industrial Biosciences today announced receipt of a grant from the Bill & Melinda Gates Foundation to support a new area of research. The research project, which commences immediately, aims to create new production systems to enable affordable, protein-based biologic medications, such as antibodies.
Through a grant from the Bill & Melinda Gates Foundation, DuPont will apply its world-class capabilities in the areas of protein engineering, pathway engineering and cell factories to the field of protein drugs.
The DuPont Industrial Biosciences business is a world leader in the manufacture and scale up of industrial proteins. When applied to pharmaceutical protein production, this approach has the potential to enable rapid scale-up and lower costs at high volumes, making protein drugs such as monoclonal antibodies potentially suitable for infectious diseases, effectively managing outbreaks and providing affordable supply to people around the world.
“We cannot underestimate the complexity of this challenge. At the same time, we cannot turn our backs on the possibility of improving access and affordability of life-saving medications for communities around the world,” said William F. Feehery, president, DuPont Industrial Biosciences. “This is cutting-edge science. We are honored to work with a leading organization like The Gates Foundation to tackle this type of issue, as no one company or entity can get there on their own.”
The Bill & Melinda Gates Foundation has long recognized that solving the world’s greatest global health and development issues is a long-term effort, and they have shown enormous commitment to the discovery of new drugs through strategic partnerships and grants like this one. The foundation seeks ideas and solutions from diverse fields, investing in discovery research through a variety of mechanisms. DuPont has been at the forefront of scientific advancement for 214 years, applying the latest innovation to global challenges. In a time when public-funded research is diminishing, companies like DuPont are engaging in new ways with stakeholders across the public and private sectors to tackle large societal challenges.
DuPont Industrial Biosciences works with customers across a wide range of industries to make products and industrial processes more efficient and sustainable. Through a unique combination of agriculture, biotechnology, chemistry and material science capabilities, we advance market-driven, biobased solutions to meet the needs of a growing population, while protecting our environment for future generations. For updates about how DuPont Industrial Biosciences is helping customers deliver cost-effective products with superior performance and sustainability, follow @DuPontBiobased on Twitter or visit our website at http://biosciences.dupont.com.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.
Forward-Looking Statements: This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on December 11, 2015, with The Dow Chemical Company pursuant to which the companies have agreed to effect an all-stock merger of equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and timely realize the expected benefits of the proposed transaction and risks related to the intended business separations contemplated to occur after the completion of the proposed transaction. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
For the original version on PRWeb visit: http://www.prweb.com/releases/dupont-industrial-biosci/gates-foundation-grant/prweb13929265.htm